| WB | 1/200-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | HPAO; SSAO; VAP1; VAP-1 |
| WB Predicted band size | 85 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human AOC3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于AOC3抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**：*VAP-1/SSAO Antibody Therapy Attenuates Inflammation and Fibrosis in a Mouse Model of Chronic Liver Injury*
**作者**：Salmi, M., Jalkanen, S., et al.
**摘要**：该研究通过小鼠模型证明，抗AOC3(VAP-1)抗体可显著抑制慢性肝损伤中的炎症反应和纤维化进程。实验显示，抗体通过阻断VAP-1介导的白细胞黏附与迁移，减少促炎细胞因子释放，提示其作为肝纤维化治疗的潜在靶点。
---
2. **文献名称**：*Targeting Vascular Adhesion Protein-1 (VAP-1) with Antibodies Inhibits Leukocyte Trafficking and Improves Diabetic Retinopathy Outcomes*
**作者**：Smith, R.A., et al.
**摘要**：研究利用抗AOC3抗体抑制VAP-1活性，发现其可有效减少糖尿病视网膜病变模型中白细胞的异常浸润和血管渗漏。结果显示，抗体治疗可改善视网膜微血管功能，为糖尿病并发症提供新治疗策略。
---
3. **文献名称**：*AOC3 as a Therapeutic Target in Solid Tumors: Anti-VAP-1 Antibody Enhances T Cell Infiltration and Antitumor Immunity*
**作者**：Wang, L., Chen, D., et al.
**摘要**：该文献报道抗AOC3抗体通过阻断肿瘤微环境中VAP-1介导的免疫抑制信号，促进细胞毒性T细胞向肿瘤组织浸润，增强免疫检查点抑制剂的疗效，为实体瘤联合免疫治疗提供了实验依据。
---
(注：上述文献为示例，实际引用需根据具体研究补充完整信息。建议通过PubMed或Google Scholar以关键词“AOC3 antibody”或“VAP-1 therapeutic”检索最新论文。)
The AOC3 antibody targets the AOC3 protein, also known as Vascular Adhesion Protein-1 (VAP-1) or Semicarbazide-sensitive amine oxidase (SSAO), a membrane-bound enzyme expressed in endothelial, smooth muscle, and adipose tissues. AOC3 plays dual roles: it catalyzes the oxidation of primary amines into aldehydes, hydrogen peroxide, and ammonia, and facilitates leukocyte trafficking across vascular barriers by mediating adhesion and transmigration during inflammation. Dysregulation of AOC3 is linked to chronic inflammatory diseases, diabetic complications, liver fibrosis, and cancer metastasis, making it a therapeutic target.
AOC3 antibodies are widely used in research to study the protein's expression, localization, and function in disease models. They enable detection of AOC3 in tissues or biofluids, aiding in biomarker studies. Therapeutic AOC3-blocking antibodies have been explored to inhibit its enzymatic or adhesion functions, potentially mitigating inflammation-driven pathologies. For example, in diabetic retinopathy, AOC3 inhibition reduces leukocyte infiltration and vascular damage. Commercially available AOC3 antibodies vary in specificity (e.g., targeting extracellular domains for functional studies or intracellular regions for expression analysis). Challenges include cross-reactivity with related amine oxidases and variability in tissue-specific isoforms. Recent advances focus on humanized antibodies for clinical applications, with several preclinical studies showing promise in autoimmune and fibrotic diseases.
×
